Autolus Therapeutics hosted a virtual investor event on April 8, 2026, spotlighting its Acute Lymphoblastic Leukemia business, featuring real-world data on AUCATZYL from the ROCCA registry and expert discussions on treatment landscape.
Key takeaways
Hosted 'Spotlight on the Acute Lymphoblastic Leukemia (ALL) Business' virtual investor event on April 8, 2026, with presentation as Exhibit 99.1.
ROCCA registry covers ~60% of U.S. commercial AUCATZYL patients; 96 apheresed since Nov 2024, 91 infused twice, 84 evaluable at D28.
Real-world patients older (median 50) and more pretreated (68% ≥3 lines) than FELIX trial (median 47, 35% ≥3 lines).
Low disease burden at infusion key for outcomes; CAR-T supports durable remission without transplant in MRD-negative cases.
AUCATZYL addresses safety, manufacturing reliability, persistence, and access challenges versus competitors.
Experts predict CAR-T shift to earlier lines and product biology as key differentiator.